In a retrospective study, researchers evaluated the impact of specific KRAS mutations among 392 patients with advanced and recurrent colorectal cancer. They detected KRAS mutation in 42.9% of tumors and found that KRAS mutation was predictive of overall survival (HR, 1.54; P = .005). Specifically, worse overall survival was associated with KRAS codon 12 mutations (HR, 1.76; P = .001). Common codon 12 mutations that predicted overall survival included p.G12C (HR, 2.21; P = .01) and p.G12V (HR, 1.69; P = .02).
Researchers concluded that codon 12 mutations p.G12C and p.G12V are independently associated with worse overall survival among patients with colorectal cancer.
http://www.nature.com/bjc/journal/vaop/ncurrent/full/bjc201737a.html
